Former FDA, CMS chief Mark McClellan appointed to Cigna’s board

Mark McClellan, MD, a former CMS administrator and a former Commissioner of the FDA, was appointed to Cigna’s board of directors, where he will begin his term Dec. 1. 

Earlier this year, Cigna announced its acquisition of Express Scripts for $67 billion. If the deal closes before McClellan’s start date, he will join the board of directors of the combined company at closing.

“Mark’s combination of healthcare industry and economic expertise will strongly support Cigna’s efforts to drive healthcare affordability and quality, as we continue to innovate and deliver differentiated value for our customers, clients and communities—in alignment with healthcare providers,” said Cigna President and CEO David M. Cordani in a prepared statement.

McClellan, a physician and economist, is currently the director of the Robert J. Margolis MD Center for Health Policy at Duke University.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”